Introduction: The rise of recent novel therapies teclistamab, elranatamab, and talquetamab for the treatment of relapsed/refractory multiple myeloma (RRMM) is a rapidly evolving area with significant clinical implications that require exploration and evaluation.
Areas covered: The current review highlights the clinical trial data, safety endpoints, and practical administration considerations for the bispecific therapies currently used in multiple myeloma. This article reviewed the efficacy and safety results between the three different bispecifics, and the differences in dosing and monitoring requirements. Adverse event management for the bispecific antibodies will be explored including the need for antimicrobial prophylaxis, premedication, and IVIG replacement. Future considerations for widespread bispecific administration and ongoing clinical trials are discussed.
Expert opinion: Practical considerations for bispecific administration such as hospitalization requirements, monitoring of adverse events, and medication considerations are emphasized. Future directions and clinical implications regarding the pivotal role of these agents will be discussed.
Keywords: Elranatamab; Multiple myeloma; Talquetamab; Teclistamab; bispecific monoclonal antibodies; cytokine release syndrome (CRS); immune effector cell-associated neurotoxicity syndrome (ICANS).